Biomoda, Inc. Announces Relationship with Los Alamos National Laboratories.

ALBUQUERQUE, N.M. -- Reissuing release to add ticker symbol for searching purposes.

The corrected release reads:

BIOMODA, INC. ANNOUNCES RELATIONSHIP WITH LOS ALAMOS NATIONAL LABORATORIES

Biomoda, Inc. (OTCBB: BMOD) of Albuquerque, N.M., developer of early lung cancer detection testing and other cancer diagnostic technology, announced today that it has signed an agreement to exclusively license cancer detection technology from Los Alamos National Laboratory.

Biomoda's cancer detection technology is based on a patented porphyrin application that preferentially binds to cancerous or aberrant cells, which are non-invasively collected from lung sputum samples. The porphyrin then glows red under fluorescent light, easily identifying cancerous cells. This simple optical reading of a molecular cancer test is easily automated, permitting rapid, accurate, and inexpensive cancer screening of large populations.

"Our agreement highlights the importance of our National Laboratories, particularly Los Alamos, and the significant contribution made by them to medical research and product development," said John Cousins, President of Biomoda. "It was a researcher from Los Alamos who 15 years ago began his investigation into the lung ailments of miners in Colorado that led to Biomoda's technology that detects lung cancer at its earliest stages."

Los Alamos National Security, LLC, a team composed of four top U.S. organizations with extensive experience in nuclear defense programsCoBechtel National, University of California, BWX Technologies, and Washington Group InternationalCois the new management and operating (M&O) contractor, and is committed to the Laboratory's continued legacy of excellence.

Lung cancer claims more lives than any other cancer. An estimated 162,460 deaths from lung cancer will occur in the United States during 2006. The expected five year survival rate for all patients combined in whom lung cancer is diagnosed is 15 percent and by contrast, the five year survival rate for cases detected when the disease is still localized is 50 percent. At the present time, only 16 percent of lung cancer cases are diagnosed at this early stage.

For additional information, visit the Biomoda web site at www.biomoda.com.

"Safe Harbor" Statement: This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are naturally subject to uncertainty and changes in circumstances. Actual results may vary materially from expectations contained herein. Biomoda is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.